Αρχική Uncategorized Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for... UncategorizedWorld News Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer Από Ogkologos - 25 Αυγούστου, 2026 202 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENZAMET (ANZUP 1304) study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR Latest episode of our podcast for cancer researchers 23 Μαρτίου, 2022 Lack of Benefit of Adding Immune Checkpoint Inhibitors to Chemotherapy in... 6 Δεκεμβρίου, 2021 EMA Recommends Granting a Marketing Authorisation for Phesgo (Pertuzumab / Trastuzumab) 19 Νοεμβρίου, 2020 Celebrating 10 years of partnership with NIVEA Sun 14 Οκτωβρίου, 2022 Φόρτωση περισσοτέρων HOT NEWS The Cancer Moonshot: A Midpoint Progress Update EMA Recommends Extending Indications for Pembrolizumab to Include Adjuvant Treatment in... Let’s Talk About Bubbles ΣΤΑΤΙΣΤΙΚΑ